Arcellx (ACLX) TD Cowen 45th Annual Healthcare Conference summary

Strategic objectives and product positioning

• Focused on launching anito-cel as a category-defining BCMA therapy for multiple myeloma, emphasizing best-in-class efficacy and safety over the next few years.

• Aims to invest for long-term growth, with pipeline expansion into AML, autoimmune diseases, and solid tumors.

• Manufacturing partnership with Kite enables rapid, scalable production, supporting broad patient access.

• Market opportunity estimated at $12B+, with potential to exceed $20B as therapies move into earlier treatment lines.

• Attractive deal structure and partnership with Kite-Gilead seen as underappreciated strengths.

Clinical data highlights and safety profile

• Phase I results showed a 30.2-month median PFS, 62% CR rate, 93.1% MRD negativity, and strong safety in high-risk patients.

• No delayed neurotoxicities observed in over 155 patients, with a differentiated safety profile compared to competitors.

• Three times the rate of no CRS and half the rate of ICANS versus other BCMA CAR-Ts.

• Upcoming data updates expected mid-year at EHA and again by year-end, with follow-up comparable to CARTITUDE-1.

• Safety and efficacy data will continue to mature, with subgroup analyses planned as data matures.

Competitive landscape and differentiation

• Delayed neurotoxicity and Parkinsonism rates are significantly lower than with Carvykti, attributed to binder differences.

• Real-world data and case series highlight persistent safety issues with Carvykti, not seen with anito-cel.

• Prophylactic steroid regimens do not mitigate Carvykti’s delayed neurotoxicity, and mechanistic differences support anito-cel’s safety.

• Manufacturing turnaround time is under 17 days, outperforming competitors’ 4–6 week timelines.

• Access and scalability are key advantages, with plans to be in twice as many centers as some competitors.